A Phase 1 interventional study of Test Drug (Eutropin Catridge, 48IU/Cartridge) and Reference Drug (Eutropin, 4 IU/vial) in Healthy Volunteers, sponsored by LG Chem. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-17.
Sponsored by LG Chem · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, Open Label, Single Subcutaneous Dose, 2x2 Crossover Study to Investigate the Relative Bioavailability, Safety and Tolerability among Different Eutropin Formulations in Healthy Volunteers
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single subcutaneous dose of the Test Drug(T), in the first period, followed by a washout period, and then a single subcutaneous dose of the Reference Drug(R) in the second period.
Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge) · Drug: Reference Drug (Eutropin, 4 IU/vial)
Participants receive a single subcutaneous dose of the Reference Drug(R), in the first period, followed by a washout period, and then a single subcutaneous dose of the Test Drug(T) in the second period.
Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge) · Drug: Reference Drug (Eutropin, 4 IU/vial)
Liqid somatropin
Also known as: T, Test Drug
Lyophilized somatropin
Also known as: R, Reference Drug
AUClast of somatropin
AUClast will be used to evaluate the pharmacokinetics of somatropin
Time frame: 0 to 24 hours post-dose
AUCinf of somatropin
AUCinf will be used to evaluate the pharmacokinetics of somatropin.
Time frame: 0 to 24 hours post-dose
Cmax of somatropin
Cmax will be used to evaluate the pharmacokinetics of somatropin.
Time frame: 0 to 24 hours post-dose
Tmax of soatropin
Tmax will be used to evaluate the pharmacokinetics of somatropin.
Time frame: 0 to 24 hours post-dose
T1/2β of somatropin
T1/2β will be used to evaluate the pharmacokinetics of somatropin.
Time frame: 0 to 24 hours post-dose
Change in IGF-1 levels
Change in IGF-1 levels will be used to evaluate the parmacodynamic effect of somatropin.
Time frame: 0 to 24 hours post-dose
Change in IGFBP-3 levels
Change in IGFBP-3 levels will be used to evaluate the parmacodynamic effect of somatropin.
Time frame: 0 to 24 hours post-dose
Ran from Jan 2025 to primary completion in Apr 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.